It kommende tiidrek fan persoanlike genetyske genêskunde
December 18, 2025 · Frisian News
Gene sequencing costs have fallen from millions to hundreds of dollars, pushing hospitals and clinics worldwide to adopt personalized treatment plans based on individual DNA. The shift promises better outcomes but raises tough questions about who pays, who has access, and who controls the data.
FryskIn 54-jierrige frou yn Kopenhagen kaam ferline maitiid har kankerklinyk yn mei har persoanlik genoomrapport yn de hân. It tumor-DNA toande in mutaasje dy't gefoelich wie foar in medisyn dat se noch nea heard hie, in medisyn dat standert behannelprotokollen nea foarskreaun hawwe soenen. Se begûn mei it nije medisyn, en seis moannen letter wiene har scans skjin. Dy saak werhellet him no tûzenen kearen yn de moanne, yn sikehûzen yn Jeropa, Azië en Noard-Amearika. De kosten foar folslein genoomsequencing binne sakke fan 3 miljoen dollar yn 2003 nei minder as 200 dollar hjoed, en dy daling toant gjin teken fan stopjen.
Sikehûzen wurkje hurd om genetyske laboratoaria op te bouwen en spesjalisten oan te nimmen om de gegevens te lêzen. Fersekeringsmaatskippijen wrakselje om te bepalen hokker testen sy dekke sille. Farmaceutyske bedriuwen trainearje har folsleine ferkeapteams opnij, om't medisinen net mear yn nette kategoryen passe. In middel tsjin kanker dat earder 'boarstkankerpasjinten' behandele, wurdt no foarskreaun oan froulju wier tumoren in spesifike genetyske flater hawwe, nettsjinsteande wêr't de kanker begûn. De âlde oanpak, it behanneljen fan sykten nei hoe't se derút sjogge, stjert gau. De nije behannelet sykte nei wat it op molekulêr nivo is.
Dochs skept de ferskowing skerpe problemen. Yn rike lannen wurdt genetysk testen binnen fiif jier standertbehanneling. Yn earme lannen sjogge pasjinten it nea. In Somalyske boer mei deselde kanker as de Kopenhagen-frou sil wierskynlik nea har kâns krije op dat op maat makke medisyn. Sels yn rike lannen ûntsteane grutte fragen oer macht. Wa't eigner is fan de genetyske gegevens? Techbedriuwen en sikehûsnetwurken stride al om eigendomsrjochten, en regearingen hâlde it net by mei regels. As in bedriuw jo genoom besit, kin it ynsjoch ferkeapje oan fersekerers? Kin de plysje it easkje sûnder rjochterlik befel?
De wittenskip wurket. Oerlibingspersintaazjes springje omheech as dokters genetyske gegevens brûke om medisinen en dosearringen te kiezen. De kosten sakje mei de tiid as de technology rypt. Dochs bliuwt de tagong ûngelikens en sil dat desennia lang sa bliuwe. In pasjint op it plattelân fan Missouri sil minder foardiel hawwe fan dizze revolúsje as in wolhawwende bewenner fan Londen. De kleau tusken dyjingen dy't persoanlike genetyske genêskunde betelje kinne en dyjingen dy't dat net kinne, sil groeie foardat dy ôfnimt.
Genêskunde yn 2030 sil hiel oars derút sjen as genêskunde yn 2020. Dokters sille yndividuen behannelje, net syktesoarten. De revolúsje is echt en de foardielen binne echt. Mar like echt is it risiko dat it in lúksegoed wurdt, beskikber foar guon en ferbean foar oaren.
A 54-year-old woman in Copenhagen walked into her cancer clinic last spring with her personal genome report in hand. Her tumor DNA showed a mutation that made it vulnerable to a drug she had never heard of, one that standard treatment protocols would never have prescribed. She started the new drug, and six months later, her scans came back clear. That case repeats itself thousands of times each month now, across hospitals in Europe, Asia, and North America. The cost of full genome sequencing has crashed from $3 million in 2003 to under $200 today, and that fall shows no sign of stopping.
Hospitals race to build genetic labs and hire specialists to read the data. Insurance companies struggle to decide which tests they will cover. Pharmaceutical firms retrain their entire sales teams because drugs no longer fit neat categories. A cancer drug that once targeted "breast cancer patients" now gets prescribed to women whose tumors carry a specific genetic fault, regardless of where the cancer started. The old approach, treating disease by what it looks like, dies fast. The new one treats disease by what it is made of at the molecular level.
Yet the shift creates sharp problems. In wealthy nations, genetic testing becomes standard care within five years. In poor ones, patients never see it. A Somali farmer with the same cancer as the Copenhagen woman will likely never get her chance at that tailored drug. Even in rich countries, questions of power loom large. Who owns the genetic data? Tech firms and hospital networks already fight over ownership rights, and governments have not caught up with rules. If a company owns your genome, can it sell insights to insurers? Can police demand it without a warrant?
The science works. Survival rates jump when doctors use genetic data to pick drugs and doses. Costs fall over time as the technology matures. Yet access remains unequal and will stay that way for decades. A patient in rural Missouri will get less benefit from this revolution than a wealthy resident of London. The gap between those who can afford personal genetic medicine and those who cannot will grow before it shrinks.
Medicine in 2030 will look nothing like medicine in 2020. Doctors will treat individuals, not disease categories. The revolution is real and the benefits are real. But so is the risk that it becomes a luxury good, available to some and forbidden to others.
Published December 18, 2025 · Frisian News · Ljouwert, Fryslân